
The European Commission has approved Ravicti for rare urea cycle disorders. Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

